Oral tiludronate: pharmacological properties and potential usefulness in Paget's disease of bone and osteoporosis.

Suppr

超能文献

作者信息

Reginster J Y

机构信息

Bone Metabolism Unit, University of Liege, Belgium.

出版信息

Bone. 1992;13(5):351-4. doi: 10.1016/8756-3282(92)90450-b.

DOI:10.1016/8756-3282(92)90450-b

PMID:1419375

Abstract

摘要

相似文献

Oral tiludronate: pharmacological properties and potential usefulness in Paget's disease of bone and osteoporosis.

Bone. 1992;13(5):351-4. doi: 10.1016/8756-3282(92)90450-b.

Comparative clinical pharmacology and therapeutic use of bisphosphonates in metabolic bone diseases.

Drugs. 1996 Apr;51(4):537-51. doi: 10.2165/00003495-199651040-00003.

Tiludronate. A new treatment for an old ailment: Paget's disease of bone.

Expert Opin Pharmacother. 1999 Nov;1(1):157-70. doi: 10.1517/14656566.1.1.157.

Alendronate reaches U.S. market for osteoporosis, Paget's disease.

Am J Health Syst Pharm. 1995 Nov 15;52(22):2513-4. doi: 10.1093/ajhp/52.22.2513.

Bisphosphonates in the treatment of metabolic bone diseases.

Ann Med. 1993 Aug;25(4):373-8. doi: 10.3109/07853899309147299.

Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone.

Bone Miner. 1994 May;25(2):75-82. doi: 10.1016/s0169-6009(08)80249-8.

Tiludronate for Paget's disease of bone.

Med Lett Drugs Ther. 1997 Jul 18;39(1005):65-6.

Tiludronate therapy for Paget's disease of bone.

Bone. 1995 Nov;17(5 Suppl):493S-496S. doi: 10.1016/8756-3282(95)00282-1.

Skeletal safety of tiludronate.

Bone. 1995 Nov;17(5 Suppl):501S-503S. doi: 10.1016/8756-3282(95)00343-7.

[Perspectives on therapy with diphosphonates in non-malignant diseases].

Z Gerontol. 1990 Jan-Feb;23(1):39-42.

引用本文的文献

Bone-Seeking Matrix Metalloproteinase-2 Inhibitors Prevent Bone Metastatic Breast Cancer Growth.

Mol Cancer Ther. 2017 Mar;16(3):494-505. doi: 10.1158/1535-7163.MCT-16-0315-T. Epub 2017 Jan 9.

Assessment of a bone biopsy technique for measuring tiludronate in horses: a preliminary study.

Can J Vet Res. 2011 Apr;75(2):128-33.

Risedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral administration.

Pharm Res. 2001 Feb;18(2):166-70. doi: 10.1023/a:1011024200280.

Effect of renal function on risedronate pharmacokinetics after a single oral dose.

Br J Clin Pharmacol. 2000 Mar;49(3):215-22. doi: 10.1046/j.1365-2125.2000.00135.x.

Esophageal irritation due to alendronate sodium tablets: possible mechanisms.

Dig Dis Sci. 1998 Sep;43(9):1998-2002. doi: 10.1023/a:1018894827961.

Comparative study of potential for bisphosphonates to damage gastric mucosa of rats.

Dig Dis Sci. 1998 May;43(5):1009-15. doi: 10.1023/a:1018826600877.

Parathyroid hormone in the treatment of involutional osteoporosis: back to the future.

Osteoporos Int. 1997;7 Suppl 3:S163-8. doi: 10.1007/BF03194365.

Risedronate gastrointestinal absorption is independent of site and rate of administration.

Pharm Res. 1998 Feb;15(2):228-32. doi: 10.1023/a:1011910517200.

A double-blind, multicentre, placebo-controlled study of tiludronate in Paget's disease of bone.

Postgrad Med J. 1997 Aug;73(862):496-502. doi: 10.1136/pgmj.73.862.496.

The role of bisphosphonates in the prevention and treatment of osteoporosis.

Clin Rheumatol. 1995 Sep;14 Suppl 3:22-5. doi: 10.1007/BF02210684.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验